Silence Therapeutics (SLN) Assets (2018 - 2026)

Silence Therapeutics has disclosed Assets across 9 years of filings, most recently posting $115.1 million for Q1 2026.

• Assets for Q1 2026 came in at $115.1 million, down 37.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.1 million (down 37.87% YoY), and the FY2025 annual result was $131.4 million, down 35.13% from the prior year.
• Assets came in at $115.1 million for Q1 2026 at Silence Therapeutics, down from $131.4 million in the prior quarter.
• In the past five years, Assets ranged from a high of $202.6 million in Q4 2024 to a low of $115.1 million in Q1 2026.
• The 5-year median for Assets is $139.1 million (2025), against an average of $148.6 million.
• Across the five-year window, Assets jumped 74.01% in 2024 and sank 37.87% in 2026, its largest moves.
• Silence Therapeutics' Assets stood at $126.1 million in 2022, then retreated by 7.65% to $116.4 million in 2023, then surged by 74.01% to $202.6 million in 2024, then tumbled by 35.13% to $131.4 million in 2025, then decreased by 12.42% to $115.1 million in 2026.
• The last three Assets figures came in at $115.1 million (Q1 2026), $131.4 million (Q4 2025), and $146.8 million (Q3 2025), per Business Quant data.